arrasy, Biotime's CEO Dr. West founded Geron and also was a CEO of ACTC, over the years he has acquired much of his earlier companies IP. There is still a chance BTX will absorb ACTC imo. Recyte is a BTX subsidiary that will focus on tissue engineering which Robert Lanza knows something about. Look for Robert to rejoin Dr. West sometime this year and take the industry by storm.
btimnext, thanks for your reply. I like your first scenario, a BTX merger with ACTC, much better. If Dr. Lanza were to leave ACTC I suspect that my significant investment there would drop like a rock. Verrrry interesting.